Earnings calendar/VRTX
VERTEX PHARMACEUTICALS INC / MA (VRTX)
Quarter-by-quarter results read from the company's own filed statements — period end, filing date, diluted EPS, revenue and year-over-year change. Consensus estimates are shown only where one exists.
Latest filed quarter
The most recent quarter VERTEX PHARMACEUTICALS INC / MA has filed, from EvidInvest's standardized statements.
Period end
Jun 30, 2026
Q2 FY2026
EPS (diluted)
$4.31
Est. $4.74 · -9.1%
Revenue
$3.33B
Est. $3.23B · +3.2%
Net income
$1.10B
As filed
EPS YoY
+8.0%
vs quarter ended 2025-06-30
Revenue YoY
+12.5%
vs quarter ended 2025-06-30
Next report
Nov 2, 2026
Scheduled · est. EPS $4.77
Run-rate
Trailing twelve months, summed from the last four filed quarters.
TTM EPS (diluted)
$17.17
2025-09-30 through 2026-06-30
TTM revenue
$12.59B
2025-09-30 through 2026-06-30
Filed quarters
40
On record here
EPS at or above estimate (4Q)
0%
Of the last four quarters that carry an estimate
Filed quarters
One row per filed statement, newest first
| Period end | Filed | EPS diluted | Revenue | EPS YoY | Revenue YoY | Est. EPS | Surprise |
|---|---|---|---|---|---|---|---|
| 2026-06-30Q2 FY2026 | 2026-08-04 | $4.31 | $3.33B | +8.0% | +12.5% | $4.74 | -9.1% |
| 2026-03-31Q1 FY2026 | 2026-05-05 | $4.02 | $2.99B | +61.4% | +7.8% | $4.24 | -5.2% |
| 2025-12-31Q4 FY2025 | 2026-02-13 | $4.64 | $3.19B | +28.2% | +9.5% | $4.98 | -6.8% |
| 2025-09-30Q3 FY2025 | 2025-11-04 | $4.20 | $3.08B | +4.7% | +11.0% | $4.57 | -8.1% |
| 2025-06-30Q2 FY2025 | 2025-08-05 | $3.99 | $2.96B | +128.7% | +12.1% | $4.29 | -7.0% |
| 2025-03-31Q1 FY2025 | 2025-05-06 | $2.49 | $2.77B | -40.9% | +3.0% | $4.25 | -41.4% |
| 2024-12-31Q4 FY2024 | 2025-02-13 | $3.62 | $2.91B | -2.4% | +15.7% | $4.02 | -10.0% |
| 2024-09-30Q3 FY2024 | 2024-11-05 | $4.01 | $2.77B | +1.0% | +11.6% | $4.14 | -3.1% |
| 2024-06-30Q2 FY2024 | 2024-08-02 | $-13.92 | $2.65B | -495.5% | +6.1% | $-11.63 | -19.7% |
| 2024-03-31Q1 FY2024 | 2024-05-07 | $4.21 | $2.69B | +56.5% | +13.3% | $4.06 | +3.7% |
| 2023-12-31Q4 FY2023 | 2024-02-15 | $3.71 | $2.52B | +18.2% | +9.3% | $4.10 | -9.5% |
| 2023-09-30Q3 FY2023 | 2023-11-07 | $3.97 | $2.48B | +10.6% | +6.4% | $3.97 | 0.0% |
| 2023-06-30Q2 FY2023 | 2023-08-02 | $3.52 | $2.49B | +12.5% | +13.5% | $3.88 | -9.3% |
| 2023-03-31Q1 FY2023 | 2023-05-02 | $2.69 | $2.37B | -9.1% | +13.2% | $3.00 | -10.3% |
| 2022-12-31Q4 FY2022 | 2023-02-10 | $3.14 | $2.30B | +5.4% | +11.1% | $3.51 | -10.5% |
| 2022-09-30Q3 FY2022 | 2022-10-28 | $3.59 | $2.33B | +9.5% | +17.7% | $3.64 | -1.4% |
| 2022-06-30Q2 FY2022 | 2022-08-05 | $3.13 | $2.20B | +1103.8% | +22.5% | $3.48 | -10.1% |
| 2022-03-31Q1 FY2022 | 2022-05-06 | $2.96 | $2.10B | +18.9% | +21.6% | $3.49 | -15.2% |
| 2021-12-31Q4 FY2021 | 2022-02-09 | $2.98 | $2.07B | +29.6% | +27.3% | $3.30 | -9.7% |
| 2021-09-30Q3 FY2021 | 2021-11-03 | $3.28 | $1.98B | +29.6% | +29.0% | $3.08 | +6.5% |
| 2021-06-30Q2 FY2021 | 2021-07-30 | $0.26 | $1.79B | -91.8% | +17.6% | $2.69 | -90.3% |
| 2021-03-31Q1 FY2021 | 2021-04-30 | $2.49 | $1.72B | +8.7% | +13.8% | $2.69 | -7.4% |
| 2020-12-31Q4 FY2020 | 2021-02-11 | $2.30 | $1.63B | +3.1% | +15.2% | $2.59 | -11.2% |
| 2020-09-30Q3 FY2020 | 2020-10-30 | $2.53 | $1.54B | +1050.0% | +62.0% | $2.34 | +8.1% |
| 2020-06-30Q2 FY2020 | 2020-07-31 | $3.18 | $1.52B | +208.7% | +62.0% | $2.07 | +53.6% |
| 2020-03-31Q1 FY2020 | 2020-05-01 | $2.29 | $1.52B | +122.3% | +76.5% | $1.85 | +23.8% |
| 2019-12-31Q4 FY2019 | 2020-02-13 | $2.23 | $1.41B | -62.6% | +62.4% | $1.21 | +84.3% |
| 2019-09-30Q3 FY2019 | 2019-10-31 | $0.22 | $949.8M | -56.0% | +21.1% | $1.14 | -80.7% |
| 2019-06-30Q2 FY2019 | 2019-08-01 | $1.03 | $941.3M | +28.7% | +25.1% | $1.07 | -3.7% |
| 2019-03-31Q1 FY2019 | 2019-05-01 | $1.03 | $858.4M | +27.2% | +34.0% | $0.97 | +6.2% |
| 2018-12-31Q4 FY2018 | 2019-02-13 | $5.97 | $870.1M | +1430.8% | +33.5% | $1.05 | +468.6% |
| 2018-09-30Q3 FY2018 | 2018-10-25 | $0.50 | $784.5M | +222.0% | +35.7% | $1.00 | -50.0% |
| 2018-06-30Q2 FY2018 | 2018-07-26 | $0.80 | $752.2M | +1042.9% | +38.2% | $0.75 | +6.7% |
| 2018-03-31Q1 FY2018 | 2018-04-27 | $0.81 | $640.8M | -18.2% | -10.3% | $0.63 | +28.6% |
| 2017-12-31Q4 FY2017 | 2018-02-15 | $0.39 | $651.6M | +200.0% | +42.1% | $0.58 | -32.8% |
| 2017-09-30Q3 FY2017 | 2017-10-30 | $-0.41 | $578.2M | -156.2% | +39.7% | $0.37 | -210.8% |
| 2017-06-30Q2 FY2017 | 2017-07-28 | $0.07 | $544.1M | — | — | $0.35 | -80.0% |
| 2017-03-31Q1 FY2017 | 2017-04-28 | $0.99 | $714.7M | — | — | $0.29 | +241.4% |
| 2016-12-31Q4 FY2016 | 2017-02-23 | $0.13 | $458.7M | — | — | $0.26 | -50.0% |
| 2016-09-30Q3 FY2016 | 2016-10-31 | $-0.16 | $413.8M | — | — | $0.19 | -184.2% |
Need VRTX data in your own agent or pipeline?
The earnings data on this page — report dates, filed EPS/revenue actuals and run-rate history — is also available programmatically through the EvidInvest MCP server & financial data API for Claude, Cursor, or any MCP client and HTTP pipeline.